**4. Conclusion**

*Non-Coding RNAs*

**106**

**Cancer**

**lncRNAs**

**Head/**

**Gastric**

**Lung**

**Breast**

**Pancreas**

**Liver**

**Colon**

**Uterine**

**Ovarian**

x

x

**Osteosarcoma**

**Prostate**

**Bladder**

**Renal**

**SNC**

**Leukemia**

**Refs.**

[99,

100]

[101,

102]

**neck**

PCA3 PCAT-1

TUG1

XIST **Table 1.**

*lncRNAs with potential to be used as biomarkers, in several types of cancer.*

x

x

x

x

x

x

x

x

x

x

x

x

x

[105]

x

x

x

x

x

x

x

x

x

x

x

x

x

x

[103,

104]

x

x

x

x

x

x

x

x

x

x

x

The vast number of studies describing lncRNAs associated with several tumor types and regulating several processes of cancer cells is shown here. The great advance in RNA sequencing technology allows us to identify new molecules and characterized better lncRNAs. From the discovery of these molecules, in the beginning, they appeared to have no important functions; however, today many researches in this area propose that more information about these molecules may help us understand numerous characters of tumor cells that are still unknown. Some lncRNAs are associated with several hallmarks of cancer demonstrating the importance of these molecules in the mechanism of disease, like MALAT and HOTAIR. Other are already utilized as biomarker in prostate cancer like PCA3. Considering the challenges for *in vivo* experimental designs, lncRNAs continue to be promising as biomarkers and potential therapeutic targets.
